

Ospemifene: an alternative option for the treatment of vulvovaginal atrophy

Graziottin A.

Ospemifene: an alternative option for the treatment of vulvovaginal atrophy

Graziottin A. (a cura di), Atti e approfondimenti di farmacologia del corso ECM su "Patologie ginecologiche benigne e dolore: come scegliere il meglio fra terapie mediche e chirurgiche", organizzato dalla Fondazione Alessandra Graziottin per la cura del dolore nella donna Onlus, Milano, 25 maggio 2018, p. 97-103

Vulvar and vaginal atrophy (VVA) is a chronic medical condition in women suffering from hypoestrogenism. The main sufferers of VVA are postmenopausal women which have a permanent reduced systemic oestrogen level (more than 50% of all postmenopausal women).

Ospemifene is a systemic selective oestrogen receptor modulator (SERM) that recently became available in Europe for moderate to severe symptomatic VVA in post-menopausal women who are not candidates for local vaginal oestrogen therapy.